“`html
Summary of Clinical Trial Meta-Analysis
Overview
- Meta-analysis of six approved biologic agents for severe asthma, including tezepelumab
- Assessed efficacy and safety in patients with severe asthma
Results
- Biologics associated with:
- 44% reduction in annual asthma exacerbations
- 60% reduction in hospitalizations
- Mean increase in forced expiratory volume in 1 s
- Reduction in asthma control questionnaire scores
- Increase in asthma quality of life questionnaire scores
- Greater efficacy in patients with T2 inflammation
- Favorable safety profile
Conclusions
- Licensed asthma biologics offer practical benefits:
- Reduced exacerbations and hospitalizations
- Improved lung function, asthma control, and quality of life
- Limitation of systemic corticosteroid use
- More prominent effects in patients with evidence of T2 inflammation
“`
